Zydus Lifesciences Limited — Updates, 08-05-2025: Press Release

Zydus has announced a board meeting on the financial results for the quarter and half-year. The company secured USFDA final approval for its generic Glatiramer Acetate Injection (20 mg/ml and 40 mg/ml), a complex biosimilar to Copaxone® for multiple sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, this product targets a US market worth US$ 719 million annually. This approval boosts Zydus’ specialty generics portfolio and growth prospects in differentiated therapies.